Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Authors

Emrullah Yilmaz, Cleveland Clinic, Cleveland, OH.
Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA.
Julie E. Bauman, George Washington University, Washington, DC.
Raetasha Dabney, The Center for Cancer and Blood Disorder, Southlake, TX.
Gregory Gan, Kansas University Medical Center, Kansas City, KS.
Richard Jordan, University of California San Francisco, San Francisco, CA.
Marnie Kaufman, Patient Representative, Needham Heights, MA.
Kedar Kirtane, Moffitt Cancer Center, Tampa, FL.
Sean Matthew McBride, Memorial Sloan Kettering Cancer Center, New York, NY.
Matthew O. Old, Ohio State University, Columbus, OH.
Lisa Rooper, Johns Hopkins Medicine, Baltimore, MD.
Nabil Saba, Emory University, Atlanta, GA.
Siddharth Sheth, University of North Carolina, Chapel Hill, Chapel Hill, NC.
Rathan M. Subramaniam, Otago Medical School, University of Otago, Dunedin, New Zealand.
Trisha Michel Wise-Draper, University of Cincinnati, Cincinnati, OH.
Deborah Wong, University of California Los Angeles, Los Angeles, CA.
Loren K. Mell, University of California San Diego, La Jolla, CA.

Document Type

Journal Article

Publication Date

12-15-2022

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

DOI

10.1200/JCO.22.02328

Abstract

PURPOSE: To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers. METHODS: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 28 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: When possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence.Additional information is available at www.asco.org/head-neck-cancer-guidelines.

APA Citation

Yilmaz, Emrullah; Ismaila, Nofisat; Bauman, Julie E.; Dabney, Raetasha; Gan, Gregory; Jordan, Richard; Kaufman, Marnie; Kirtane, Kedar; McBride, Sean Matthew; Old, Matthew O.; Rooper, Lisa; Saba, Nabil; Sheth, Siddharth; Subramaniam, Rathan M.; Wise-Draper, Trisha Michel; Wong, Deborah; and Mell, Loren K., "Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline" (2022). GW Authored Works. Paper 2093.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/2093

Department

Medicine